Clinical Trials

170 enrolled

Advanced Microsatellite Stable Colorectal Cancer

NCT07529873 2026-04-14

N'FORCE

131 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07514767 2026-04-07

NOCANO

60 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

120 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT07510334 2026-04-03

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

18 enrolled

Phase 4 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07504796 2026-04-01

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

90 enrolled

Melanoma

NCT07075120 2026-03-31

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

15 enrolled

Carcinoma, Hepatocellular

NCT07176975 2026-03-31

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

46 enrolled

Other solid neoplasm

Solid Tumors

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

15 enrolled

Uveal Melanoma

NCT07494435 2026-03-27

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

230 enrolled

Carcinoma, Renal Cell

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

CNSDermatologicGastrointestinal

260 enrolled

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

68 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT07460765 2026-03-10

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

40 enrolled

Phase 4 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

30 enrolled

Melanoma, Skin Neoplasms

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Phase EARLY_PHASE1 Not yet recruiting

18 enrolled

Sarcoma

NCT07210632 2026-02-27

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

38 enrolled

CNS

Brain Neoplasms, Glioma

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07403877 2026-02-11

TORCH-OPTIMA

114 enrolled

Turcot syndrome, Colorectal Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 3 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

718 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07369791 2026-01-28

NOBLE

76 enrolled

Advanced Biliary Tract Cancer(BTC)

NCT07355205 2026-01-21

FLINN

26 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

142 enrolled

Phase NA Not yet recruiting

Advanced Kidney Cancer

NCT07233668 2025-12-03

IVE in mRCC

172 enrolled

Carcinoma, Renal Cell

NCT07219459 2025-10-21

GDFATHERHCC01

104 enrolled

Carcinoma, Hepatocellular

NCT07216833 2025-10-15

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

15 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07187869 2025-09-23

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

16 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Renal Cell

NCT07017816 2025-06-17

JACOB

18 enrolled

CNS

Neoplasms, Germ Cell and Embryonal, Pinealoma, Central Nervous System Neoplasms

NCT06692491 2024-11-18

SPRING

Phase 1/2 Not yet recruiting

200 enrolled

Rare Tumour

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

30 enrolled

Melanoma

NCT06572722 2024-08-27

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

200 enrolled

Lung Neoplasms

NCT06554613 2024-08-15

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05597800 2022-10-28

LUNGVIR

105 enrolled